The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479)
摘要:
We report the design, synthesis and evaluation of a family of ca 50 phosphoramidate ProTides of the potent anti-HCV compound 4 '-azidocytidine (R1479), with variation on the ester, amino acid and aryl moiety of the ProTide. Sub-mu M inhibitors of HCV emerge. The compounds are all non-cytotoxic in the replicon assay. We herein report detailed SARs for each of the regions of the ProTide. (C) 2009 Elsevier Ltd. All rights reserved.
Discovery of a β-<scp>d</scp>-2′-Deoxy-2′-α-fluoro-2′-β-<i>C</i>-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
作者:Michael J. Sofia、Donghui Bao、Wonsuk Chang、Jinfa Du、Dhanapalan Nagarathnam、Suguna Rachakonda、P. Ganapati Reddy、Bruce S. Ross、Peiyuan Wang、Hai-Ren Zhang、Shalini Bansal、Christine Espiritu、Meg Keilman、Angela M. Lam、Holly M. Micolochick Steuer、Congrong Niu、Michael J. Otto、Phillip A. Furman
DOI:10.1021/jm100863x
日期:2010.10.14
HepatitisCvirus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease. The HCV NS5Bpolymerase has been demonstrated to be a viable target for the development of HCV therapies. β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyl nucleosides are selective inhibitors of the HCV NS5Bpolymerase and have demonstrated potent activity in the clinic. Phosphoramidate prodrugs
丙型肝炎病毒 (HCV) 是一个全球性的健康问题,需要新的方法来有效治疗这种疾病。HCV NS5B 聚合酶已被证明是开发 HCV 疗法的可行靶标。β- d -2'-Deoxy-2'-α-fluoro-2'-β- C-甲基核苷是 HCV NS5B 聚合酶的选择性抑制剂,并已在临床上显示出有效的活性。制备了 β- d -2'-deoxy-2'-α-fluoro-2'-β- C-甲基尿苷核苷的 5'-磷酸衍生物的氨基磷酸酯前药,并在 HCV 亚基因组复制子测定中显示出显着的效力(< 1 μM)并产生高水平的三磷酸盐6当体内给药时,在原代肝细胞和大鼠、狗和猴子的肝脏中。使非对映体混合物14的单一非对映体51结晶,确定X射线结构,将氨基磷酸酯立体化学建立为S p ,从而首次将氨基磷酸酯前药的立体化学与生物活性相关联。51(PSI-7977)被选为临床开发候选者。
The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479)
作者:Christopher McGuigan、Mary Rose Kelleher、Plinio Perrone、Sinead Mulready、Giovanna Luoni、Felice Daverio、Sonal Rajyaguru、Sophie Le Pogam、Isabel Najera、Joseph A. Martin、Klaus Klumpp、David B. Smith
DOI:10.1016/j.bmcl.2009.05.099
日期:2009.8
We report the design, synthesis and evaluation of a family of ca 50 phosphoramidate ProTides of the potent anti-HCV compound 4 '-azidocytidine (R1479), with variation on the ester, amino acid and aryl moiety of the ProTide. Sub-mu M inhibitors of HCV emerge. The compounds are all non-cytotoxic in the replicon assay. We herein report detailed SARs for each of the regions of the ProTide. (C) 2009 Elsevier Ltd. All rights reserved.